Los Angeles, November 2, 2020— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases is pleased to announce that it has filed a provisional patent application with the US Patent & Trademark Office for the company’s first-in-class drug TRE-515. If granted, […]
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Tretherahttps://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngTrethera2020-11-02 04:40:002021-03-08 21:43:36Trethera Announces U.S. Patent Application Filed for TRE-515, Extending Major Markets Exclusivity until 2041
Trethera Announces U.S. Patent Application Filed for TRE-515, Extending Major Markets Exclusivity until 2041
/in News /by TretheraLos Angeles, November 2, 2020— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases is pleased to announce that it has filed a provisional patent application with the US Patent & Trademark Office for the company’s first-in-class drug TRE-515. If granted, […]